Sudy Finds Oncotype DX Diagnostic Reduces Chemotherapy Use In Young Breast Cancer Patients

Sudy Finds Oncotype DX Diagnostic Reduces Chemotherapy Use In Young Breast Cancer Patients
Oncotype-DX-Colon-Cancer-TestResearchers at the University of Texas MD Anderson Cancer have conducted a large population-based study of Oncotype DX, finding it was significantly linked to a reduced use of chemotherapy in younger breast cancer patients. These findings will be presented by Mariana Chavez Mac Gregor, M.D., assistant professor, during the 2014 San Antonio Breast Cancer Symposium. Oncotype DX is a 21-gene assay that is used to calculate the probability of disease recurrence in women suffering with early-stage lymph node-negative, hormone receptor (HR)-positive and HER2-negative breast cancer, allowing physicians to define who will actually benefit from adjuvant chemotherapy. “The results allow physicians to stratify this patient group into low, intermediate and high risk of recurrence, as well as understand a woman’s potential personal benefit from chemotherapy in the adjuvant setting. With this study, we wanted to evaluate the use of Oncotype DX in the general population to see if there’s a relationship between the use of the test and chemotherapy decrease in those patients,” Dr. Chavez Mac Gregor said in a
Subscribe or to access all post and page content.